Blood pressure drug joins forces with immunotherapy and radiation to fight head and neck cancer
NCT ID NCT06211335
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests whether adding a common blood pressure medication (losartan) to immunotherapy (pembrolizumab) and precise radiation (SBRT) is safe and effective for people with head and neck cancer that has returned, not responded to treatment, or spread to a few other spots. About 24 adults will receive the combination to see if it helps control the disease. The goal is to find a better way to manage this hard-to-treat cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
University of California Davis Comprehensive Cancer Center
RECRUITINGSacramento, California, 95817, United States
-
University of Colorado Denver | Anschutz Medical Campus
RECRUITINGAurora, Colorado, 80045, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Leftover immunotherapy may boost chemo: new study investigates timing
- New combo therapy aims to fight returning head and neck cancer
- Can a smaller dose of this cancer drug still work? new trial aims to find out
- Remote hearing tests could save cancer Patients' hearing
- New drug cocktail aims to extend life in Tough-to-Treat head and neck cancer
- New combo therapy shows promise for Hard-to-Treat head and neck cancer